▼Parent drug is transiently bound to linker-carrier, which inactivates and shields it from clearance
▼Following injection, the linker is designed to auto-hydrolyze at specific rates to predictably release unmodified parent drug
▼Designed to distribute parent drug compound like the endogenous compound; linker-carrier is cleared renally

▼Predictable release of unmodified parent drug supporting dosing frequency from daily to up to six months or more
▼Enables sustained localized or systemic drug exposure
▼Reduces dosing frequency to improve patient adherence and improve overall treatment outcomes

▼Same mode of action as parent drug
▼Same established safety profile as parent drug with potential enhancements or improvements due to application of TransCon technologies
▼Enables comparable alternative to continuous infusions or subcutaneous injections

▼Patent for invention（New composition of matter patents）
▼Exclusive license to develop and commercialize Ascendis Pharma’s endocrinology therapies in Greater China